Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

S, Shen; X, Chen; J, Cai; J, Yu; J, Gao; S, Hu; X, Zhai; C, Liang; X, Ju; H, Jiang; R, Jin; X, Wu; N, Wang; X, Tian; K, Pan; H, Jiang; L, Sun; Y, Fang; CK, Li; Q, Hu; M, Yang; Y, Zhu; H, Zhang; C, Li; D, Pei; S, Jeha; JJ, Yang; C, Cheng; J, Tang; X, Zhu; CH, Pui

doi:10.1001/jamaoncol.2019.5868

Public

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Shared by NobleBlocks on Mar 1, 2020 • 12:00 AM UTC

Authors:

Shen S

Chen X

Cai J

Abstract

Importance A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).Objective To d...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!